BioCryst: Strategic Shift to External Rare-Disease Assets and Cost Discipline Supports Unchanged $32 Price Target and Buy Rating
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Andrew Fein maintained a Buy rating on BioCryst with an unchanged $32 price target, citing strategic shifts toward external rare-disease assets and cost discipline. Key drivers include lower long-term R&D costs, resolved manufacturing issues for ORLADEYO pediatric pellets opening new growth segments, and reduced 2026 non-GAAP operating expense guidance while maintaining revenue expectations. Needham also maintained a Buy rating with a $16 target.
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on BioCryst, retaining the price target of $32.00.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Andrew Fein has given his Buy rating due to a combination of factors tied to BioCryst’s evolving strategy and financial profile. He views the shutdown of the Birmingham discovery facility and the pivot toward acquiring external rare‑disease assets as a disciplined move that should lower long‑term R&D costs while sharpening focus on high‑impact programs like navenibart and BCX17725, supported by robust ORLADEYO cash flows.
Fein also highlights that management has cut 2026 non‑GAAP operating expense guidance while maintaining revenue expectations, reinforcing a clearer path to durable profitability. In addition, the resolution of manufacturing issues for ORLADEYO pediatric pellets opens a meaningful new growth segment in underpenetrated U.S. pediatric HAE, which he expects to ramp with support from existing prescriber relationships. Taken together, these dynamics underpin his unchanged $32 price target and Buy recommendation.
Fein covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Savara, and Wave Life Sciences. According to TipRanks, Fein has an average return of 25.3% and a 54.36% success rate on recommended stocks.
In another report released today, Needham also maintained a Buy rating on the stock with a $16.00 price target.